ʻO ka nasopharyngeal (nay-zoh-fuh-RIN-jee-ul) ka maʻi maʻi maʻi e ulu ana ma ka nasopharynx, aia ma hope o kou ihu a ma luna o ke kua o kou puʻu.
He kakaikahi ka nasopharyngeal carcinoma ma United States.Loaʻa pinepine ʻia ma nā wahi ʻē aʻe o ka honua - ʻo Asia Hikina Hema.
He paʻakikī ke ʻike mua ʻia ka maʻi maʻi maʻi nasopharyngeal.ʻO ia paha no ka maʻalahi ʻole o ka nasopharynx e nānā a ʻike ʻia nā hōʻailona o ka carcinoma nasopharyngeal i nā ʻano maʻi ʻē aʻe.
Loaʻa ka nasopharyngeal carcinoma ma waena o ka poʻe ʻelemakule a me nā poʻe ʻelemakule ma mua o 40 mau makahiki, a he ʻano ʻāpana ʻāina a me ka ʻohana, a ʻo ka nui o ka maʻi ma Guangdong ke kūlana mua ma Kina, i kapa ʻia ʻo "Guangdong cancer".
1. ʻO nā alakaʻi no ka ʻike a me ka mālama ʻana i ka maʻi maʻi maʻi Nasopharyngeal
I ka 2021 Guidelines for the Diagnosis and Treatment of Nasopharyngeal Carcinoma, ka Chinese Society of Clinical Oncology (CSCO) i komo i ka serological detection method in the Class I hoike no ka maʻi o ka nasopharyngeal carcinoma, a kuhikuhi i ka hui pū ʻana o EB-VCA-IgA. a me EB-NA1-IgA EB-virus antibodies hiki ke hoʻonui i ka helu o ka maʻi maʻi mua o ka nasopharyngeal carcinoma e 3 mau manawa (21% ~ 79%) a hoʻemi i ka hopena o ka make ma 88%!ʻO ka 2019 Expert Consensus on the Clinical Application of Markers for Nasopharyngeal Carcinoma i hōʻike pū ʻia ʻo EBV-EA-IgA kahi hōʻailona o ka maʻi EBV hou a i ʻole ka hoʻonui nui ʻana o EBV, me kahi kiʻekiʻe o ka kikoʻī, a hoʻohana pinepine ʻia no ka nānā ʻana i ka maʻi kanesa nasopharyngeal. a me ka ʻike mua.
Hōʻike ka haʻawina i nā ʻike hui ʻekolu o EBV-VCA-IGA, EBV-EA-IGA a me EB-NA1-IgA e uhi piha i ka EBV gene spectrum, kahi e hoʻomaikaʻi maikaʻi ai i ka naʻau a me ka kikoʻī o ka ʻike ʻana i ka carcinoma nasopharyngeal, hōʻemi i ka ʻike nalo, e hōʻoia i ka pololei o ka wanana maʻi, a wanana i ka hiki mai o ka maʻi 5-10 makahiki ma mua, i mea kūpono no ka nui-nui nasopharyngeal maʻi 'aʻai maʻi 'ana screening.
2. ʻO ka VCA-IgA + EA-IgA + NA1-IgA i hana ʻia e Beijing Beier hiki ke hāʻawi i ka protocol diagnostic early for Nasopharyngeal Carcinoma.
Mākēneki particulate immuno chemistry luminescence ala
| inoa mea kūʻai | Pōʻokoʻa |
| EB virus VCA-IgA mea ʻike antibody | EB-VCA-IgA |
| EB virus EA-IgA antibody detection kit | EB-EA-IgA |
| EB virus NA1-IgA mea ʻike kino kino | EB-NA1-IgA |
Hana ʻo Elisa:
| inoa mea kūʻai | Pōʻokoʻa |
| EB virus VCA-IgA Elisa kit | EB-VCA-IgA |
| EB virus EA-IgA Elisa kit | EB-EA-IgA |
| EB virus NA1-IgA Elisa kit | EB-NA1-IgA |
3.Hana Hana
Hiki i ka pahu ho'āʻo VCA-IgA i hana ʻia e Beijing Beier ke pani i ka pahu maʻamau o EU no ka ʻike mua ʻana a me ka nānā ʻana i ka maʻi maʻi maʻi nasopharyngeal.
ʻO ka British Medical Journal (BMJ) (impact factor 16.378) ʻo ia kekahi o nā puke moʻolelo olakino ʻehā o ka honua.I ka makahiki 2017, ua paʻi kahi hui noiʻi i kahi pepa ma ka British Medical Journal (BMJ) "Evaluation of seven recombinant VCA-IgA ELISA kits for the diagnostic of nasopharyngeal carcinoma in China: a case-control trial".
I loko o kēia pepa, ua aʻo ʻia a hoʻāʻo ʻia nā mea maʻi 200 me ka nasopharyngeal carcinoma (NPC) a me 200 maʻamau kanaka serum samples (SYSUCC) mai Sun Yat-sen University Cancer Center, a me ka hana o nā pahu EB-VCA-IgA (ELISA) i hana ʻia e 8 ua hoʻohālikelike ʻia nā mea hana brand ma ka mākeke kūloko no ka loiloi hana.ʻO ka hopena, ʻo ka pahu EBV-VCA-IgA (ELISA) i hana ʻia e Beijing Beier ka hopena diagnostic like me ka EBV-VCA-IgA (ELISA) i hana ʻia e ka reagent Oumeng i lawe ʻia mai, a me ka EBV-VCA-IgA (ELISA) kit i hana ʻia e Beijing Beier hiki ke hoʻololi i ka pahu i lawe ʻia mai no ka ʻike mua ʻana a me ka nānā ʻana i ka maʻi maʻi nasopharyngeal carcinoma.Hōʻike ʻia ka ʻike o nā mea hana hōʻailona e komo ana i ka hoʻāʻo ma ka Papa 1, hōʻike ʻia nā hopena hōʻike ma ka Papa 2, a hōʻike ʻia nā hopena hōʻike ma ka Papa 3.
Ka hopena hoao
ʻEkolu kits VCA-IgA recombinant-BB,HA a me KSB- i loaʻa nā hopena diagnostic e like me nā mea o ka pahu maʻamau. Hiki ke hoʻololi iā lākou no ka pahu maʻamau a hiki ke hoʻohana ʻia kā lākou hui ʻana i ka ʻike mua ʻana o ka NPC.
Ka manawa hoʻouna: Feb-23-2023